Novel biologics for the treatment of pediatric severe asthma

Amelia Licari; Riccardo Castagnoli; Enrico Tondina; Giorgia Testa; Giuseppe Fabio Parisi; Alessia Marseglia; Ilaria Brambilla; Gian Luigi Marseglia

doi:10.2174/1573398X15666190521111816

Novel biologics for the treatment of pediatric severe asthma

Amelia Licari, Riccardo Castagnoli, Enrico Tondina, Giorgia Testa, Giuseppe Fabio Parisi, Alessia Marseglia, Ilaria Brambilla, Gian Luigi Marseglia

Research output: Contribution to journal › Review article › peer-review

Abstract

Estimated to represent less than 5% of all asthmatic patients, children with severe asthma experience troublesome persistent symptoms, life-threatening attacks and side effects by oral corticosteroid treatment, that significantly impact on the quality of life and on economic costs. An accurate understanding of the mechanisms of the disease has been crucial for the discovery and development of biological therapies, for which children with severe asthma are candidates. The aim of this review is to discuss the use of approved biologics for severe asthma, providing updated evidence of novel targeted therapies in the pediatric age range.

Original language	English
Pages (from-to)	195-204
Number of pages	10
Journal	Current Respiratory Medicine Reviews
Volume	15
Issue number	3
DOIs	https://doi.org/10.2174/1573398X15666190521111816
Publication status	Published - 2019

Keywords

Benralizumab
Children
Dupilumab
Mepolizumab
Omalizumab
Reslizumab
Severe asthma

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.2174/1573398X15666190521111816

Cite this

@article{3868c1860339441d962b8490a95ad05e,

title = "Novel biologics for the treatment of pediatric severe asthma",

abstract = "Estimated to represent less than 5% of all asthmatic patients, children with severe asthma experience troublesome persistent symptoms, life-threatening attacks and side effects by oral corticosteroid treatment, that significantly impact on the quality of life and on economic costs. An accurate understanding of the mechanisms of the disease has been crucial for the discovery and development of biological therapies, for which children with severe asthma are candidates. The aim of this review is to discuss the use of approved biologics for severe asthma, providing updated evidence of novel targeted therapies in the pediatric age range.",

keywords = "Benralizumab, Children, Dupilumab, Mepolizumab, Omalizumab, Reslizumab, Severe asthma",

author = "Amelia Licari and Riccardo Castagnoli and Enrico Tondina and Giorgia Testa and Parisi, {Giuseppe Fabio} and Alessia Marseglia and Ilaria Brambilla and Marseglia, {Gian Luigi}",

note = "Publisher Copyright: {\textcopyright} 2019 Bentham Science Publishers.",

year = "2019",

doi = "10.2174/1573398X15666190521111816",

language = "English",

volume = "15",

pages = "195--204",

journal = "Current Respiratory Medicine Reviews",

issn = "1573-398X",

publisher = "Bentham Science Publishers B.V.",

number = "3",

}

TY - JOUR

T1 - Novel biologics for the treatment of pediatric severe asthma

AU - Licari, Amelia

AU - Castagnoli, Riccardo

AU - Tondina, Enrico

AU - Testa, Giorgia

AU - Parisi, Giuseppe Fabio

AU - Marseglia, Alessia

AU - Brambilla, Ilaria

AU - Marseglia, Gian Luigi

PY - 2019

Y1 - 2019

N2 - Estimated to represent less than 5% of all asthmatic patients, children with severe asthma experience troublesome persistent symptoms, life-threatening attacks and side effects by oral corticosteroid treatment, that significantly impact on the quality of life and on economic costs. An accurate understanding of the mechanisms of the disease has been crucial for the discovery and development of biological therapies, for which children with severe asthma are candidates. The aim of this review is to discuss the use of approved biologics for severe asthma, providing updated evidence of novel targeted therapies in the pediatric age range.

AB - Estimated to represent less than 5% of all asthmatic patients, children with severe asthma experience troublesome persistent symptoms, life-threatening attacks and side effects by oral corticosteroid treatment, that significantly impact on the quality of life and on economic costs. An accurate understanding of the mechanisms of the disease has been crucial for the discovery and development of biological therapies, for which children with severe asthma are candidates. The aim of this review is to discuss the use of approved biologics for severe asthma, providing updated evidence of novel targeted therapies in the pediatric age range.

KW - Benralizumab

KW - Children

KW - Dupilumab

KW - Mepolizumab

KW - Omalizumab

KW - Reslizumab

KW - Severe asthma

UR - http://www.scopus.com/inward/record.url?scp=85078556094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078556094&partnerID=8YFLogxK

U2 - 10.2174/1573398X15666190521111816

DO - 10.2174/1573398X15666190521111816

M3 - Review article

AN - SCOPUS:85078556094

VL - 15

SP - 195

EP - 204

JO - Current Respiratory Medicine Reviews

JF - Current Respiratory Medicine Reviews

SN - 1573-398X

IS - 3

ER -

Novel biologics for the treatment of pediatric severe asthma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this